Log in to save to my catalogue

POS1350 UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTIC...

POS1350 UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTIC...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1136_annrheumdis_2022_eular_3049

POS1350 UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTICENTER STUDY OF 80 PATIENTS

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_crossref_primary_10_1136_annrheumdis_2022_eular_3049

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1136_annrheumdis_2022_eular_3049

Other Identifiers

ISSN

0003-4967

DOI

10.1136/annrheumdis-2022-eular.3049

How to access this item